id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-028328-5lews3uw	Haas, Andrew R.	COMMUNITY-ACQUIRED PNEUMONIA	2020-06-22		.txt	text/plain	5067	257	40	With the development of the fl uoroquinolones, effective high levels of lung penetration have been achieved without the development of resistance to treat even those patients with severe pneumonia using a single agent once a day (except those with risk factors for P. Although an antipneumococcal fl uoroquinolone would be equally effective, use of one of these agents in this Chapter 78 Community-Acquired Pneumonia 1085 Practice: Therapy of Infectious Diseases low-risk patient population is likely unnecessary and may promote selection pressure for resistance. Recognition of the clinical syndrome consistent with pneumonia, assessing patients' risk factors for specifi c organisms, determining their medical comorbidities, and evaluating their severity of illness will allow the clinician to ascertain pertinent pathogens and choose appropriate empirical coverage for CAP. A fi ve-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit	./cache/cord-028328-5lews3uw.txt	./txt/cord-028328-5lews3uw.txt